Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Jenny C. Chang"'
Autor:
Emre Koca, Virginia G. Kaklamani, Adam L. Cohen, Sindhu Nair, Jorge Darcourt, Asha Murthy, Anna Belcheva, Helen Wong, Toniva Boone, Joe Ensor, Pej Hemati, Polly A. Niravath, Wei Qian, Priya V. Ramshesh, Jing Zhao, Jenny C. Chang, Tejal Patel, Xiaoxian Li
Publikováno v:
Breast Cancer Research and Treatment. 188:433-439
Neoadjuvant endocrine therapy is often utilized to downstage Estrogen Receptor-positive (ER+) breast cancer prior to surgery. However, this approach is sometimes met with endocrine resistance mechanisms within the tumor. This trial examines the safet
Autor:
Jianying Zhou, Tejaswini P. Reddy, Hongbin Wang, Stacy L. Moulder, Wei Qian, Roberto R. Rosato, Jenny C. Chang, Helen Piwnica-Worms, Liliana Guzman
Publikováno v:
Cancer Research. 81:PS11-17
Metaplastic breast cancer (MpBC) is a rare subset accounting for less than 1% of all breast cancers. MpBC exhibits the worst prognosis in comparison to triple-negative breast cancer (TNBC) with a dismal poor survival rate in patients with metastatic
Autor:
Ivo W. Tremont-Lukats, Charisma Mylavarapu, Jiagiong Xu, Polly A. Niravath, Bin S. Teh, Tejal Patel, Jenny C. Chang, Akshjot Puri
Publikováno v:
Cancer Research. 81:PS14-08
BACKGROUNDImprovements in systemic therapies have led to significantly improved survival in patients with breast cancer and have created a challenge with regards to management of brain metastases (BM) and leptomeningeal disease (LMD). LMD is a highly
Autor:
Roberto Rangel, Wei Qian, Jessica Bronstad, Jianying Zhou, Liliana Guzman, Jenny C. Chang, Roberto R. Rosato
Publikováno v:
Cancer Research. 81:PS17-30
Breast cancer is the second leading cause of cancer-related deaths in the United States. The Cancer Genome Atlas (TCGA) network has classified breast cancer into four main subtypes: luminal A, luminal B, HER2+, and Triple- negative breast cancer (TNB
Publikováno v:
The Breast Journal. 26:1793-1796
Metastatic triple-negative breast cancer (mTNBC) patients tend to have a poor overall survival. The primary goals of treatment focus on palliation of symptoms and improvement in overall survival (OS). Single-agent sequential chemotherapy with anthrac
Autor:
Olufunmilayo I. Olopade, Vassily V. Trubetskoy, Rita Nanda, Jenny C. Chang, Douglas E. Merkel, E. Claire Dees, Minetta C. Liu, Nancy J. Cox, M. Eileen Dolan, R. Stephanie Huang, Antonio C. Wolff, Olwen Hahn, Andres Forero, Julianne P. Hall, Phuong Khanh Morrow, Vandana G. Abramson, Gini F. Fleming, Peter H. O'Donnell, Gary L. Rosner, James N. Ingle, Jeffrey Peppercorn, Aritro Nath, Philip C. Hoffman, Mark J. Ratain, Hope S. Rugo, Catherine Van Poznak, Ashley Nurhussein-Patterson, Dezheng Huo, Anna Maria Storniolo
Publikováno v:
Breast Cancer Research and Treatment. 181:623-633
Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity using a novel monitoring tool. P
Autor:
Edward T. McLean, Susan Xu, Rosetta Lee, Polly A. Niravath, Jenny C. Chang, Tejal Patel, Ethan Burns
Publikováno v:
Cancer Research. 80:P5-12
Introduction The results of the SOFT and TEXT trials created a paradigm shift in the management of pre-menopausal women with estrogen (ER) or progesterone (PR) receptor positive breast cancer. With findings demonstrating reduced recurrence in high ri
Autor:
Isaura Fernandez-Perez, Pier Adelchi Ruffini, Giuseppe Viale, Beth Butler, Jenny C. Chang, Mauro Mansutti, Christelle Levy, Susan McCanna, Anne F. Schott, Stephanie Henry, Lori J. Goldstein, Guiseppe Viale, Max S. Wicha
Publikováno v:
Cancer Research. 80:P3-11
Background: CXCR1, one of the receptors for CXCL8, has been identified as a druggable target on breast cancer Cancer Stem Cells (CSC): In a phase 1b study, the combination of reparixin (R), an investigational oral inhibitor of CXCR1, and weekly pacli
Autor:
Andrew M. Farach, Mary R. Schwartz, Albert C. Chen, Bin S. Teh, Gary D. Lewis, Yan Xing, E. Brian Butler, Jenny C. Chang, Sandra S. Hatch, Tejal Patel, Waqar Haque
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-9 (2019)
Cancer Communications
Cancer Communications
Background Invasive micropapillary carcinoma (IMPC) is an uncommon subtype of breast cancer. Previous studies of this subtype demonstrated a higher propensity for lymph node metastases as compared with invasive ductal carcinoma (IDC). The purpose of
Autor:
Tejal Patel, Edward T. McLean, Polly A. Niravath, Ethan Burns, Jenny C. Chang, Rosetta Lee, Emre Koca, Jiaqiong Xu
Publikováno v:
Oncologist
Purpose This study evaluated the proportion of premenopausal women who experience persistent ovarian escape (OE) while receiving ovarian suppression (OS) therapy for estrogen receptor-positive (ER+) breast cancer treatment. The study also examined cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3f6788f81c5085e231fa00da189088
https://europepmc.org/articles/PMC8176991/
https://europepmc.org/articles/PMC8176991/